|
7791 |
Subjective Efficacy of Zolpidem in Outpatients with Chronic Insomnia
Enthalten in Clinical drug investigation Bd. 13, 8.11.2012, Nr. 3, date:3.1997: 134-144
|
|
|
|
7792 |
Subjective response to alcohol in young adults with bipolar disorder and recent alcohol use: a within-subject randomized placebo-controlled alcohol administration study
Enthalten in Psychopharmacology Bd. 240, 25.1.2023, Nr. 4, date:4.2023: 739-753
|
|
|
|
7793 |
Sublingual Buprenorphine Efficacy in Renal Colic Pain Relief: A Randomized Placebo-Controlled Clinical Trial
Enthalten in Pain and therapy Bd. 6, 20.10.2017, Nr. 2, date:12.2017: 227-234
|
|
|
|
7794 |
Sublinguale Folie reduziert Off-Episoden bei Parkinson-Erkrankung
Enthalten in Info Neurologie & Psychiatrie Bd. 22, 25.5.2020, Nr. 5, date:5.2020: 18-19
|
|
|
|
7795 |
Suicide attempts in clinical trials with paroxetine randomised against placebo
Enthalten in BMC medicine Bd. 3, 22.8.2005, Nr. 1, date:12.2005: 1-5
|
|
|
|
7796 |
Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries
Enthalten in Malaria journal Bd. 14, 26.11.2015, Nr. 1, date:12.2015: 1-13
|
|
|
|
7797 |
Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial
Enthalten in Targeted oncology Bd. 18, 2.9.2023, Nr. 5, date:9.2023: 639-641
|
|
|
|
7798 |
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
Enthalten in Advances in therapy Bd. 41, 8.1.2024, Nr. 3, date:3.2024: 928-931
|
|
|
|
7799 |
Summary of Research: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin Versus Placebo and the DPP-4 Inhibitor Linagliptin Versus Placebo in Young People with Type 2 Diabetes (DINAMO): A Multicentre, Randomised, Double-Blind, Parallel Group, Phase 3 Trial
Enthalten in Diabetes therapy Bd. 15, 5.4.2024, Nr. 5, date:5.2024: 893-896
|
|
|
|
7800 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Enthalten in BMC cancer Bd. 16, 31.8.2016, Nr. 1, date:12.2016: 1-13
|
|
Administration
